SEC 13F Intelligence

Managers / Q4 2022 · view latest →

BML Capital Management, LLC

CIK 0001616824 · 65 E CEDAR - SUITE 2, ZIONSVILLE, IN, 46077 · 317-344-2447

Reported Value
$105M
Q4 2022
Positions
25
Filings on Record
16
2019–present window
Filed
Feb 13, 2023
original filing

Summary

Bml Capital Management, LLC reported $105M in U.S.-listed holdings across 25 positions for Q4 2022.

Its largest position, ANF, represents 12.5% of the portfolio.

Portfolio Metrics

Top-10 Concentration
+81.0%
share of reported value
Largest Position
+12.5%
Abercrombie Fitch

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $105MQ4 ’22Q1 ’23: $116MQ2 ’23: $111MQ2 ’23Q3 ’23: $109MQ4 ’23: $132MQ4 ’23Q1 ’24: $152MQ2 ’24: $140MQ2 ’24Q3 ’24: $170MQ4 ’24: $161MQ4 ’24Q1 ’25: $124MQ2 ’25: $132MQ2 ’25Q3 ’25: $109MQ4 ’25: $116MQ4 ’25Q1 ’26: $156Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 57.8%Other: 33.5%ETP: 8.7%
  • Common Stock · 57.8% · $60M
  • Other · 33.5% · $35M
  • ETP · 8.7% · $9M

Quarter-over-Quarter Changes full breakdown →

IssuerMoveShare ΔShares nowValue ΔValue now
ANFABERCROMBIE & FITCH CONEW+571.1K571.1K+$13M$13M
IMARA INCNEW+3.02M3.02M+$12M$12M
TILLYS INCNEW+1.15M1.15M+$10M$10M
IRONDISC MEDICINE INCNEW+500.0K500.0K+$10M$10M
SPDR SER TRNEW+100.0K100.0K+$9M$9M
PARDES BIOSCIENCES INCNEW+4.87M4.87M+$8M$8M
CLYMELIEM THERAPEUTICS INCNEW+1.83M1.83M+$7M$7M
STSAUSDSATSUMA PHARMACEUTICALS INCNEW+6.44M6.44M+$6M$6M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2022

25 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ANFABERCROMBIE & FITCH COhistory →CL A12.50%$13M571.1K
2IMARA INCCOM11.79%$12M3.02M
3TILLYS INCCL A9.98%$10M1.15M
4IRONDISC MEDICINE INChistory →COM9.50%$10M500.0K
5SPDR SER TRBLOOMBERG 1-3 MO8.74%$9M100.0K
6PARDES BIOSCIENCES INCCOM7.86%$8M4.87M
7CLYMELIEM THERAPEUTICS INChistory →COM6.40%$7M1.83M
8STSAUSDSATSUMA PHARMACEUTICALS INChistory →COM5.54%$6M6.44M
9SESEN BIO INCCOM4.79%$5M8.23M
10ADVMCHFADVERUM BIOTECHNOLOGIES INChistory →COM3.91%$4M7.07M
11VERRICA PHARMACEUTICALS INCCOM2.92%$3M1.11M
12METACRINE INCCOM2.64%$3M6.17M
13ATHIRA PHARMA INCCOM2.16%$2M714.8K
14ASTCASTROTECH CORPhistory →COM2.10%$2M220.4K
15ABIOEURARCA BIOPHARMA INChistory →COM1.94%$2M858.3K
16RELLRICHARDSON ELECTRS LTDhistory →COM1.94%$2M95.4K
17TOCAEURFORTE BIOSCIENCES INChistory →COM1.40%$1M1.46M
18RVPRETRACTABLE TECHNOLOGIES INChistory →COM1.05%$1M668.6K
19MISTMILESTONE PHARMACEUTICALS INCOM0.68%$712,800180.0K
20GRAYBUG VISION INCCOMMON0.59%$617,9721.24M
21LSTALISATA THERAPEUTICS INCCOM0.59%$616,913243.8K
22PASSAGE BIO INCCOM0.44%$465,704337.5K
23TORCEURADICET BIO INCCOM0.26%$268,20030.0K
24SPRUCE BIOSCIENCES INCCOM0.23%$243,436221.8K
25ELEVATION ONCOLOGY INCCOM0.04%$37,96540.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$156M16May 6, 202613F-HRchanges · EDGAR ↗
Q4 2025$116M16Feb 3, 202613F-HRchanges · EDGAR ↗
Q3 2025$109M20Nov 10, 202513F-HRchanges · EDGAR ↗
Q2 2025$132M24Aug 11, 202513F-HRchanges · EDGAR ↗
Q1 2025$124M27May 7, 202513F-HRchanges · EDGAR ↗
Q4 2024$161M25Feb 7, 202513F-HRchanges · EDGAR ↗
Q3 2024$170M29Nov 5, 202413F-HRchanges · EDGAR ↗
Q2 2024$140M28Aug 7, 202413F-HRchanges · EDGAR ↗
Q1 2024$152M32Apr 24, 2024RESTATEMENTchanges · EDGAR ↗
Q4 2023$132M35Feb 2, 2024RESTATEMENTchanges · EDGAR ↗
Q3 2023$109M26Oct 23, 202313F-HRchanges · EDGAR ↗
Q2 2023$111M31Jul 24, 202313F-HRchanges · EDGAR ↗
Q1 2023$116M31Apr 14, 202313F-HRchanges · EDGAR ↗
Q4 2022$105M25Feb 13, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.